{"id":33232,"date":"2020-07-25T13:44:59","date_gmt":"2020-07-25T11:44:59","guid":{"rendered":"http:\/\/shekulliagency.com\/?p=33232"},"modified":"2020-07-25T13:45:01","modified_gmt":"2020-07-25T11:45:01","slug":"testet-per-vaksinat-kunder-covid-19-japin-shprese","status":"publish","type":"post","link":"https:\/\/alb.shekulliagency.com\/?p=33232","title":{"rendered":"Testet p\u00ebr vaksinat kund\u00ebr COVID-19 japin shpres\u00eb"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

Rezultatet e faz\u00ebs s\u00eb dyt\u00eb t\u00eb vaksinave kund\u00ebr COVID-19 t\u00eb publikuara n\u00eb fillim t\u00eb k\u00ebsaj jave jan\u00eb shum\u00eb inkurajuese dhe premtuese, sipas nj\u00eb eksperti mjek\u00ebsor turk.<\/p>\n\n\n\n

“Nd\u00ebrsa studimet e vaksinimit vazhdojn\u00eb intensivisht me pritje dhe shpresa t\u00eb m\u00ebdha, rezultatet premtuese t\u00eb fituara n\u00eb studimet e faz\u00ebs s\u00eb hershme n\u00eb lidhje me dy studimet u publikuan n\u00eb revist\u00ebn prestigjioze shkencore ‘Lancet'”, tha Dr. Atila Taner Kalayc\u0131o\u011flu p\u00ebr Anadolu Agency (AA).<\/p>\n\n\n\n

“N\u00ebse gjith\u00e7ka shkon mir\u00eb n\u00eb testimin e Faz\u00ebs III, sikur n\u00eb Faz\u00ebn I dhe II, n\u00eb rastin m\u00eb t\u00eb mir\u00eb, ne mund t\u00eb kemi nj\u00eb vaksin\u00eb kund\u00ebr koronavirusit deri n\u00eb fund t\u00eb vitit ose n\u00eb muajt e par\u00eb t\u00eb vitit 2021”, tha ligj\u00ebruesi i Fakultetit t\u00eb Farmacis\u00eb n\u00eb Universitetin Teknik t\u00eb Karadenizit.<\/p>\n\n\n\n

Kalayc\u0131o\u011flu tha se n\u00eb mes t\u00eb pandemis\u00eb, studiuesit po punojn\u00eb aq shpejt sa t\u00eb munden t\u00eb zhvillojn\u00eb vaksin\u00ebn.<\/p>\n\n\n\n

“Situata nuk \u00ebsht\u00eb e pashpres\u00eb. Tani masa m\u00eb e mir\u00eb kund\u00ebr virusit nuk \u00ebsht\u00eb t\u00eb ndeshesh me t\u00eb. Ne kemi arm\u00eb t\u00eb fuqishme. Tani ne e dim\u00eb virusin dhe sjelljet e tij, por zhvillimi i nj\u00eb vaksine nuk mund t\u00eb jet\u00eb gjithnj\u00eb di\u00e7ka e leht\u00eb”, tha deklaroi ai.<\/p>\n\n\n\n

Gjat\u00eb pandemis\u00eb s\u00eb gripit t\u00eb derrave n\u00eb vitin 2009, zhvillimi i nj\u00eb vaksine zgjati gjasht\u00eb muaj p\u00ebrkund\u00ebr faktit se zhvillimi i vaksin\u00ebs kund\u00ebr gripit nuk \u00ebsht\u00eb i v\u00ebshtir\u00eb, tha ai.<\/p>\n\n\n\n

Sipas Organizat\u00ebs Bot\u00ebrore t\u00eb Sh\u00ebndet\u00ebsis\u00eb (OBSH), aktualisht, nuk ka vaksin\u00eb p\u00ebr parandalimin e koronavirusit. Ekzistojn\u00eb 142 vaksina potenciale n\u00eb vler\u00ebsim para-klinik dhe 24 n\u00eb vler\u00ebsim klinik.<\/p>\n\n\n\n

Dy studime t\u00eb vaksinave jan\u00eb b\u00ebr\u00eb nga Universiteti i Oksfordit me mb\u00ebshtetje nga AstraZeneca, si dhe nd\u00ebrmarrja kineze e vaksinave CanSino Biologics.<\/p>\n\n\n\n

Gjetjet nga Oksford-AstraZeneca treguan se vaksina e adenovirusit \u00ebsht\u00eb e sigurt dhe shkakton nj\u00eb p\u00ebrgjigje imune p\u00ebr t\u00eb luftuar COVID-19.<\/p>\n\n\n\n

Gjithsej 1.077 persona, t\u00eb mosh\u00ebs nga 18 deri 55 vje\u00e7, pa histori t\u00eb infeksionit me koronavirus, u p\u00ebrfshin\u00eb n\u00eb Faz\u00ebn I dhe II n\u00eb testet e studimit. Subjektet zhvilluan antitrupa dhe qeliza-T neutralizuese q\u00eb mund t\u00eb luftojn\u00eb virusin, sipas rezultateve t\u00eb publikuara n\u00eb “The Lancet”.<\/p>\n\n\n\n

CanSino Biologics p\u00ebrdori nj\u00eb qasje t\u00eb ngjashme me vektorin e adenovirusit p\u00ebr zhvillimin e vaksin\u00ebs s\u00eb saj dhe zbuloi t\u00eb dh\u00ebna q\u00eb sugjerojn\u00eb rezultate t\u00eb ngjashme n\u00eb nj\u00eb studim t\u00eb Faz\u00ebs II.<\/p>\n\n\n\n

“Q\u00eb t\u00eb dyja raportojn\u00eb raste t\u00eb pafavorshme lokale dhe sistemike, si\u00e7 jan\u00eb ethe, lodhje dhe dhimbje n\u00eb vendin e injeksionit. N\u00eb asnj\u00eb testim nuk u raportua p\u00ebr efekte t\u00eb r\u00ebnda an\u00ebsore”, sipas “The Lancet”.<\/p>\n\n\n\n

“N\u00eb p\u00ebrgjith\u00ebsi, rezultatet e t\u00eb dy testeve jan\u00eb gjer\u00ebsisht t\u00eb ngjashme dhe premtuese, pavar\u00ebsisht nga dallimet n\u00eb vektor, n\u00eb vendet gjeografike t\u00eb popullsive t\u00eb testuara dhe p\u00ebrdorimin e analizave t\u00eb neutralizimit”, shtoi revista.<\/p>\n\n\n\n

Rezultatet i kan\u00eb bindur studiuesit t\u00eb vazhdojn\u00eb n\u00eb Faz\u00ebn III, tha Kalayc\u0131o\u011flu.<\/p>\n\n\n\n

\u201cZhvillimi klinik \u00ebsht\u00eb nj\u00eb proces trefazor. Gjat\u00eb Faz\u00ebs I, grupe t\u00eb vogla njer\u00ebzish marrin vaksin\u00ebn testuese. N\u00eb Faz\u00ebn II, studimi klinik zgjerohet dhe vaksina u jepet personave q\u00eb kan\u00eb karakteristika (si mosha dhe sh\u00ebndeti fizik) t\u00eb ngjashme me ato p\u00ebr t\u00eb cil\u00ebt synohet vaksina e re. N\u00eb Faz\u00ebn III, vaksina u jepet mij\u00ebra njer\u00ebzve dhe testohen p\u00ebr efikasitet dhe siguri”, sipas Qendr\u00ebs s\u00eb SHBA-s\u00eb p\u00ebr Kontrollin dhe Parandalimin e S\u00ebmundjeve (CDC).<\/p>\n\n\n\n

“Shum\u00eb vaksina i n\u00ebnshtrohen Faz\u00ebs IV zyrtare dhe vazhdimit t\u00eb m\u00ebtejsh\u00ebm t\u00eb studimeve pasi vaksina t\u00eb aprovohet dhe licencohet”, ka th\u00ebn\u00eb CDC.<\/p>\n\n\n\n

P\u00ebr m\u00eb tep\u00ebr, Kalayc\u0131o\u011flu tha: “N\u00eb t\u00eb dyja studimet, platforma e vektorit adenoviral, i cili \u00ebsht\u00eb nj\u00eb mjet inovativ dhe efektiv i zhvillimit t\u00eb vaksinave, u p\u00ebrdor p\u00ebr t\u00eb zhvilluar nj\u00eb vaksin\u00eb n\u00eb mes t\u00eb pandemis\u00eb s\u00eb COVID-19. Platforma e vektorit adenoviral t\u00ebrheq v\u00ebmendjen e studiuesve p\u00ebr shkak t\u00eb potencialit t\u00eb saj p\u00ebr t\u00eb stimuluar zhvillimin e reagimit imuntar natyror, humoral dhe qelizor”.<\/p>\n\n\n\n

“Kjo platform\u00eb mori vet\u00ebm licencimin rregullator t\u00eb Komisionit Evropian p\u00ebr vaksin\u00ebn kund\u00ebr Ebola m\u00eb 1 korrik 2020”, shtoi ai.<\/p>\n\n\n\n

T\u00eb pakt\u00ebn gjasht\u00eb muaj mbrojtje<\/strong><\/p>\n\n\n\n

Kalayc\u0131o\u011flu vler\u00ebson se n\u00ebse gjith\u00e7ka shkon mir\u00eb dhe zhvillohet nj\u00eb vaksin\u00eb, ajo mund t\u00eb siguroj\u00eb t\u00eb pakt\u00ebn gjasht\u00eb muaj mbrojtje.<\/p>\n\n\n\n

Ai tha se ka studime q\u00eb publikuan t\u00eb dh\u00ebna pozitive mbi provat e vaksinave t\u00eb mundshme kund\u00ebr koronavirusit n\u00eb faz\u00ebn e hershme, si\u00e7 \u00ebsht\u00eb vaksina e mundshme e kompanis\u00eb Moderna, “mRNA-1273”.<\/p>\n\n\n\n

\u201cN\u00eb vendin ton\u00eb, studimet p\u00ebr vaksin\u00ebn kund\u00ebr koronavirusit kryhen n\u00eb universitete prestigjioze. Ndoshta nj\u00eb vaksin\u00eb e sigurt dhe efektive do t\u00eb prodhohet n\u00eb Turqi”, tha ai.<\/p>\n\n\n\n

Pas zhvillimit t\u00eb vaksin\u00ebs, ajo duhet t\u00eb shp\u00ebrndahet n\u00eb gjith\u00eb bot\u00ebn n\u00eb m\u00ebnyr\u00eb t\u00eb barabart\u00eb dhe t\u00eb drejt\u00eb, k\u00ebshtu q\u00eb, nd\u00ebrsa aktualisht punohet p\u00ebr gjetjen e vaksin\u00ebs, duhet t\u00eb b\u00ebhen p\u00ebrgatitje p\u00ebr prodhimin e sasis\u00eb s\u00eb mjaftueshme t\u00eb vaksinave q\u00eb do t\u00eb d\u00ebrgohen n\u00eb bot\u00eb dhe n\u00eb vendet q\u00eb kan\u00eb nevoj\u00eb p\u00ebr t\u00eb, tha ai.<\/p>\n\n\n\n

Q\u00eb nga shfaqja e par\u00eb n\u00eb Wuhan t\u00eb Kin\u00ebs dhjetorin e kaluar, koronavirusi i ri \u00ebsht\u00eb p\u00ebrhapur n\u00eb pothuajse n\u00eb gjith\u00eb bot\u00ebn.<\/p>\n\n\n\n

M\u00eb shum\u00eb se 15,7 milion\u00eb njer\u00ebz jan\u00eb infektuar globalisht, prej t\u00eb cil\u00ebve 639.000 kan\u00eb humbur jet\u00ebn, nd\u00ebrsa 8,7 milion\u00eb jan\u00eb sh\u00ebruar, sipas shifrave t\u00eb p\u00ebrpiluara nga Universiteti Johns Hopkins me qend\u00ebr n\u00eb SHBA.<\/p>\n","protected":false},"excerpt":{"rendered":"

Rezultatet e faz\u00ebs s\u00eb dyt\u00eb t\u00eb vaksinave kund\u00ebr COVID-19 t\u00eb publikuara n\u00eb fillim t\u00eb k\u00ebsaj jave jan\u00eb shum\u00eb inkurajuese dhe premtuese, sipas nj\u00eb eksperti mjek\u00ebsor turk. “Nd\u00ebrsa studimet e vaksinimit…<\/p>\n","protected":false},"author":1,"featured_media":1642,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[31],"tags":[],"class_list":["post-33232","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-java"],"_links":{"self":[{"href":"https:\/\/alb.shekulliagency.com\/index.php?rest_route=\/wp\/v2\/posts\/33232"}],"collection":[{"href":"https:\/\/alb.shekulliagency.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alb.shekulliagency.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alb.shekulliagency.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/alb.shekulliagency.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33232"}],"version-history":[{"count":1,"href":"https:\/\/alb.shekulliagency.com\/index.php?rest_route=\/wp\/v2\/posts\/33232\/revisions"}],"predecessor-version":[{"id":33233,"href":"https:\/\/alb.shekulliagency.com\/index.php?rest_route=\/wp\/v2\/posts\/33232\/revisions\/33233"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alb.shekulliagency.com\/index.php?rest_route=\/wp\/v2\/media\/1642"}],"wp:attachment":[{"href":"https:\/\/alb.shekulliagency.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33232"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alb.shekulliagency.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33232"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alb.shekulliagency.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33232"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}